Sydmarken 11
SOeborg
Copenhagen 2860
Denmark
45 88 77 36 00
https://www.zealandpharma.com
Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 203
Name | Title | Pay | Exercised | Year born |
---|---|---|---|---|
Mr. Adam Sinding Steensberg M.D. | Pres & CEO | 741.16k | N/A | 1974 |
Ms. Henriette Wennicke | Chief Financial Officer | N/A | N/A | N/A |
Mr. Ivan Mourits Moller | Chief Operating Officer | N/A | N/A | 1972 |
Mr. Mads Kronborg | Head of Investor Relations & Communication | N/A | N/A | N/A |
Mr. Ravinder Chahil | Sr. VP & Gen. Counsel | N/A | N/A | N/A |
Ms. Christina Sonnenborg Bredal | Sr. VP and Global Head of People & Organization | N/A | N/A | 1985 |
Dr. Jens Damsgaard Mikkelsen M.D. | Head of Molecular Pharmacology | N/A | N/A | N/A |
Dr. Danilo Verge | Head of Global Medical Affairs | N/A | N/A | N/A |
Dr. David M. Kendall M.D. | Chief Medical Officer | N/A | N/A | 1962 |
Lykke Romer | VP & Head of Fin. and Accounting | N/A | N/A | N/A |
Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company markets lixisenatide under the brand names of Adlyxin and Lyxumia; Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia, congenital hyperinsulinism, and post bariatric surgery hypoglycemia; and Dasiglucagon dual-hormone artificial pancreas for automated diabetes management. The company's pipeline includes Dasiglucagon that is in Phase III clinical trials for congenital hyperinsulinism. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. Zealand Pharma A/S has collaboration agreements with Sanofi-Aventis Deutschland GmbH; Boehringer Ingelheim International GmbH; Alexion Pharmaceuticals, Inc.; and Beta Bionics, Inc. The company was incorporated in 1998 and is headquartered in Copenhagen, Denmark.
Zealand Pharma A/S’s ISS governance QualityScore as of 1 February 2023 is 3. The pillar scores are Audit: 6; Board: 1; Shareholder rights: 1; Compensation: 7.